Pembrolizumab-induced mucositis in a patient with recurrent hypopharynx squamous cell cancer

被引：8
作者：
Pelster, Meredith S. [1 ]
Mott, Frank [2 ]
Lewin, Jan [3 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Canc Med, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd Unit 0432, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA
来源：
LARYNGOSCOPE | 2020年 / 130卷 / 04期
关键词：
Pembrolizumab; mucositis; laryngeal edema; HEAD; CARCINOMA; NIVOLUMAB; SAFETY;
D O I：
10.1002/lary.28038
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Pembrolizumab, an anti-PD-1 checkpoint inhibitor, is used in patients with recurrent or metastatic squamous cell carcinoma of the head and neck who have received prior therapy with a platinum-based regimen. As a monotherapy, it is generally well tolerated, but a small percentage of patients may develop immune-mediated inflammatory reactions. We report a case of mucositis and laryngeal edema in a patient on pembrolizumab and review the literature. Laryngoscope, 130:E140-E143, 2020
引用
收藏
页码：E140 / E143
页数：4
相关论文
共 15 条
  • [1] Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
    Bauml, Joshua
    Seiwert, Tanguy Y.
    Pfister, David G.
    Worden, Francis
    Liu, Stephen V.
    Gilbert, Jill
    Saba, Nabil F.
    Weiss, Jared
    Wirth, Lori
    Sukari, Ammar
    Kang, Hyunseok
    Gibson, Michael K.
    Massarelli, Erminia
    Powell, Steven
    Meister, Amy
    Shu, Xinxin
    Cheng, Jonathan D.
    Haddad, Robert
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (14) : 1542 - +
  • [2] Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
    Baxi, Shrujal
    Yang, Annie
    Gennarelli, Renee L.
    Khan, Niloufer
    Wang, Ziwei
    Boyce, Lindsay
    Korenstein, Deborah
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2018, 360
  • [3] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
    Brahmer, Julie R.
    Lacchetti, Christina
    Schneider, Bryan J.
    Atkins, Michael B.
    Brassil, Kelly J.
    Caterino, Jeffrey M.
    Chau, Ian
    Ernstoff, Marc S.
    Gardner, Jennifer M.
    Ginex, Pamela
    Hallmeyer, Sigrun
    Chakrabarty, Jennifer Holter
    Leighl, Natasha B.
    Mammen, Jennifer S.
    McDermott, David F.
    Naing, Aung
    Nastoupil, Loretta J.
    Phillips, Tanyanika
    Porter, Laura D.
    Puzanov, Igor
    Reichner, Cristina A.
    Santomasso, Bianca D.
    Seigel, Carole
    Spira, Alexander
    Suarez-Almazor, Maria E.
    Wang, Yinghong
    Weber, Jeffrey S.
    Wolchok, Jedd D.
    Thompson, John A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) : 1714 - +
  • [4] Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab
    Brand, Fanny Zulay Acero
    Suter, Nicolas
    Adam, Jean-Philippe
    Faulques, Bernard
    Maietta, Antonio
    Soulieres, Denis
    Blais, Normand
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [5] Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
    Ferris, R. L.
    Blumenschein, G., Jr.
    Fayette, J.
    Guigay, J.
    Colevas, A. D.
    Licitra, L.
    Harrington, K.
    Kasper, S.
    Vokes, E. E.
    Even, C.
    Worden, F.
    Saba, N. F.
    Iglesias Docampo, L. C.
    Haddad, R.
    Rordorf, T.
    Kiyota, N.
    Tahara, M.
    Monga, M.
    Lynch, M.
    Geese, W. J.
    Kopit, J.
    Shaw, J. W.
    Gillison, M. L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) : 1856 - 1867
  • [6] Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Haanen, J. B. A. G.
    Carbonnel, F.
    Robert, C.
    Kerr, K. M.
    Peters, S.
    Larkin, J.
    Jordan, K.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 : 119 - 142
  • [7] Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial
    Harrington, Kevin J.
    Ferris, Robert L.
    Blumenschein, George, Jr.
    Colevas, A. Dimitrios
    Fayette, Jerome
    Licitra, Lisa
    Kasper, Stefan
    Even, Caroline
    Vokes, Everett E.
    Worden, Francis
    Saba, Nabil F.
    Kiyota, Naomi
    Haddad, Robert
    Tahara, Makoto
    Gruenwald, Viktor
    Shaw, James W.
    Monga, Manish
    Lynch, Mark
    Taylor, Fiona
    DeRosa, Michael
    Morrissey, Laura
    Cocks, Kim
    Gillison, Maura L.
    Guigay, Joel
    [J]. LANCET ONCOLOGY, 2017, 18 (08) : 1104 - 1115
  • [8] Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review
    Joshi, M. N.
    Whitelaw, B. C.
    Palomar, M. T. P.
    Wu, Y.
    Carroll, P. V.
    [J]. CLINICAL ENDOCRINOLOGY, 2016, 85 (03) : 331 - 339
  • [9] Immune-related adverse events with immune checkpoint blockade: a comprehensive review
    Michot, J. M.
    Bigenwald, C.
    Champiat, S.
    Collins, M.
    Carbonnel, F.
    Postel-Vinay, S.
    Berdelou, A.
    Varga, A.
    Bahleda, R.
    Hollebecque, A.
    Massard, C.
    Fuerea, A.
    Ribrag, V.
    Gazzah, A.
    Armand, J. P.
    Amellal, N.
    Angevin, E.
    Noel, N.
    Boutros, C.
    Mateus, C.
    Robert, C.
    Soria, J. C.
    Marabelle, A.
    Lambotte, O.
    [J]. EUROPEAN JOURNAL OF CANCER, 2016, 54 : 139 - 148
  • [10] Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
    Naidoo, J.
    Page, D. B.
    Li, B. T.
    Connell, L. C.
    Schindler, K.
    Lacouture, M. E.
    Postow, M. A.
    Wolchok, J. D.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (12) : 2375 - 2391
12